Cytori Announces New Annual Stockholders Meeting Date for July 11
June 27 2019 - 5:10PM
Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it
reconvened its annual meeting of stockholders on Thursday, June 27,
2019 and adjourned the meeting until Thursday, July 11, 2019, at
9:00 a.m., Central Time. The annual meeting was adjourned to allow
the Company’s stockholders an additional opportunity to evaluate
Proposal 4, relating to the approval of a reverse stock split of
the Company’s common stock. Although more than 69% of the
votes cast were in favor of the reverse stock split (Proposal 4),
this constitutes approximately 48% of the Company’s outstanding
shares of common stock and approval requires the affirmative vote
of a majority of the outstanding shares of common stock.
The annual meeting was adjourned until 9:00
a.m., Central Time, on July 11, 2019 at 4200 Marathon Blvd., Suite
200, Austin Texas 78756, the Company’s offices in Austin, Texas.
The record date for the annual meeting remains March 29, 2019.
Stockholders that have yet to vote are requested to do so prior to
the new July 11 meeting date and are encouraged to vote in favor of
the reverse stock split as outlined in the Company’s proxy
materials.
Stockholders who have previously sent in proxy
cards or given instructions to brokers do not need to re-cast their
votes unless they want to change their vote. Proxies
previously submitted in respect of the meeting will be voted at the
adjourned meeting unless properly revoked.
If stockholders have questions, need help voting
shares, or want to change a vote in favor of Proposal 4, please
call The Proxy Advisory Group, LLC, which is assisting the Company
in this matter at 1-888-557-7699 or 1-888-55PROXY.
About Cytori
Therapeutics, Inc.
Cytori is developing, manufacturing, and
commercializing nanoparticle-delivered oncology drugs. Cytori
is focused on the liposomal encapsulation of anti-neoplastic
chemotherapy agents or other drugs which may enable the effective
delivery of the agents to target sites while reducing systemic
toxicity and improving pharmacokinetics. Cytori’s pipeline
consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride
for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s
sarcoma, a complex/hybrid generic drug, and ATI-1123 patented
albumin-stabilized pegylated liposomal docetaxel for multiple solid
tumors. For more information, please visit
www.cytori.com.
Cytori Therapeutics, Inc.
Gary Titus, +1 (858) 458.0900ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024